메뉴 건너뛰기




Volumn 21, Issue 8, 2011, Pages 2568-2572

Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome

Author keywords

11 HSD1 inhibitor; Metabolic Syndrome; Sulfone

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; BICYCLO[2.2.2]OCTYLTRIAZOLE; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 79953283569     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.018     Document Type: Article
Times cited : (14)

References (19)
  • 12
    • 79953271197 scopus 로고    scopus 로고
    • PK parameters were based on whole blood drug levels for mouse and plasma for all other species. All the compounds were dosed as a solution in 5-30% hydroxypropyl β-cyclodextrin vehicle
    • PK parameters were based on whole blood drug levels for mouse and plasma for all other species. All the compounds were dosed as a solution in 5-30% hydroxypropyl β-cyclodextrin vehicle.
  • 18
    • 79953269099 scopus 로고    scopus 로고
    • While mouse PK was not obtained on all the compounds described in this communication, plasma levels of compound were determined in mice following the PD studies. There was generally a good correlation between efficacy and compound levels in plasma for the compounds in Tables 4 and 5; compounds with decreased plasma exposures showed lowered efficacy in extended PD
    • While mouse PK was not obtained on all the compounds described in this communication, plasma levels of compound were determined in mice following the PD studies. There was generally a good correlation between efficacy and compound levels in plasma for the compounds in Tables 4 and 5 ; compounds with decreased plasma exposures showed lowered efficacy in extended PD.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.